David Fritz, OD
Optometrist · Liberty, MONPI 1669408506
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.9% of the total across 274 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 22 manufacturers reported payments, led by Johnson & Johnson Vision Care, Inc. at 33.9% of the total. Among optometrist clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 274 payments — averaging $28.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson Vision Care, Inc.$3K
- Sun Pharmaceutical Industries Inc.$676
- Glaukos Corporation$617
- Bausch & Lomb, A Division Of Bausch Health US, LLC$574
- Novartis$541
- Oyster Point Pharma, Inc.$507
- plus $2K from 16 others
What the payments were for
- Consulting fees$2423%
- Food & beverage$7,48497%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson Vision Care, Inc. | 87 | $2,617 |
| Sun Pharmaceutical Industries Inc. | 26 | $676 |
| Glaukos Corporation | 15 | $617 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 9 | $574 |
| Novartis | 43 | $541 |
| Oyster Point Pharma, Inc. | 12 | $507 |
| AbbVie | 22 | $458 |
| Bausch & Lomb Americas Inc. | 14 | $350 |
| Tarsus Pharmaceuticals, Inc. | 11 | $201 |
| Sight Sciences, Inc. | 2 | $166 |
| Coopervision Inc. | 9 | $150 |
| ABB Con-cise Optical Group LLC | 3 | $142 |
| Harrow Eye, LLC | 2 | $137 |
| Alcon | 7 | $129 |
| Astellas Pharma US Inc | 1 | $121 |
| Topcon Healthcare, Inc. | 2 | $93 |
| Rxsight Inc | 1 | $92 |
| Kala Pharmaceuticals, Inc. | 3 | $63 |
| Shire North American Group Inc | 2 | $31 |
| Thea Pharma Inc. | 1 | $25 |
| LKC Technologies, Inc. | 1 | $22 |
| Alcon Research LLC | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BTOD$270
- TYRVAYA$269
- Acuvue$228
- CEQUA$227
- XIIDRA$226
- OMNI(R) SURGICAL SYSTEM (US)$148
- IACCESS$128
- iStent$128
- iStent inject W$128
- KXL System$128
- Izervay$121
- BIOTRUE ONE DAY$120
- VEVYE$118
- RESTASIS$113
- MIEBO$101
How this compares
$7,726 in reported general payments places this provider in the 95th percentile of 1,030 optometrist providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 36 | $31,620 |
| TyrvayaVarenicline Tartrate | 23 | $13,862 |
| Cyclosporine | 28 | $13,409 |
| LumiganBimatoprost | 11 | $6,544 |
| Travoprost | 26 | $3,090 |
| Latanoprost | 68 | $694 |
| Prednisolone Acetate | 15 | $428 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 15 | $232 |
| Timolol Maleate | 11 | $198 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 19 | $190 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan | $458 | $38,16447 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $507 | $13,86223 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,030 optometrist providers in Missouri.
Other optometrist in Liberty
- Andrew BiondoKirkwood$300K
- John McGrealSaint Louis$126K
- Alana KellerWildwood$94K
- Sarah HubbardChesterfield$91K
- Ariel CerenzieSaint Louis$76K
- Geoffrey PowellKansas City$55K
- Thomas HobbsSedalia$53K
- Heather WebsterColumbia$52K
- Sean MulqueenyCreve Coeur$45K
- Glen LojkaEllisville$45K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.